PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21779762-6	2011	The pro- and anti-arrhythmic agents flecainide and quinidine increased regional VERPs despite respectively decreasing and increasing the corresponding APD(90)s particularly in Scn5a (+/-) RV epicardia.	Quinidine	51-60	sodium channel, voltage-gated, type V, alpha	Mus musculus	176-181	
23836691-8	2013	Quinidine reduced maximum theta" in WT and caused earlier conduction failure in the RV of both Scn5a(+/-) and WT.	Quinidine	0-9	sodium channel, voltage-gated, type V, alpha	Mus musculus	95-100	
23836691-13	2013	Flecainide or quinidine decreased the pacing rates at which this occurred, through reducing basic cycle distance, in the Scn5a(+/-) RV epicardium, directly predictive of its arrhythmic phenotype.	Quinidine	14-23	sodium channel, voltage-gated, type V, alpha	Mus musculus	121-126	
22461438-7	2012	Scn5a(+/-) hearts showed greater frequencies of arrhythmic endpoints with increased incidences of ventricular tachycardia, diminished by quinidine, and earlier onsets of ventricular fibrillation, particularly following flecainide challenge.	Quinidine	137-146	sodium channel, voltage-gated, type V, alpha	Mus musculus	0-5	
20132234-14	2010	It is concluded that both flecainide and quinidine exert anti-arrhythmogenic effects in Scn3b(-/-) hearts, doing so through modifying VERP rather than DeltaAPD, in contrast to their differing effects in Scn5a(+/-) and Scn5a(+/DeltaKPQ) hearts.	Quinidine	41-50	sodium channel, voltage-gated, type V, alpha	Mus musculus	218-223	
20621962-9	2010	Both flecainide and quinidine then prevented both induced and spontaneous atrial arrhythmias in all the arrhythmic WT and Scn5a+/- hearts, in contrast to their differing ventricular effects.	Quinidine	20-29	sodium channel, voltage-gated, type V, alpha	Mus musculus	122-127	
20621962-10	2010	However, flecainide prolonged APD(90) in WT but not Scn5a+/-, whereas quinidine prolonged APD(90) in both WT and Scn5a+/-.	Quinidine	70-79	sodium channel, voltage-gated, type V, alpha	Mus musculus	113-118	
17303635-6	2007	Quinidine (10 microM) prevented VT in six out of six flecainide-treated WT and 13 out of the 16 arrhythmogenic Scn5a+/- hearts in parallel with its clinical effects.	Quinidine	0-9	sodium channel, voltage-gated, type V, alpha	Mus musculus	111-116